US › Healthcare

Kalaris Therapeutics, Inc. (KLRS)

US · Healthcare · Biotechnology

$4.32+6.67%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.9M
Profit YoY
-6.5%
EPS
$-0.46
EPS estimate
$-0.52

EPS came in at -0.46 against a street estimate of -0.52 — a beat of 11.5%.

Key statistics

Market cap
$83.5M
Forward P/E
0.0
P/B
1.22
Book value
$2.98
EPS (TTM)
$-0.79
52-week high
$11.88
52-week low
$2.14
50-day MA
$4.41
200-day MA
$6.54

Analyst view

Analysts rate Kalaris Therapeutics, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $18.71.

Shareholding

Insiders
8.82%
Institutions
77.91%

Largest institutional holders

FundStake
Samsara BioCapital, LLC54.42%
RTW INVESTMENTS, LLC5.46%
Paradigm Biocapital Advisors LP2.94%
Alyeska Investment Group, L.P.2.41%
Siren, L.L.C.1.83%
Ikarian Capital, LLC1.51%
Propel Bio Management LLC1.24%
Kalehua Capital Management LLC1.14%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kalaris Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.